Glaxis Capital Management’s Quest Diagnostics DGX Stock Holding History

Glaxis Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.17M	Buy	+5,500	New	+$1.08M	2.34%	14

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Glaxis Capital Management's DGX Position: Q2 2026 in Review

Glaxis Capital Management opened a new position in Quest Diagnostics (DGX) in Q2 2026: 5,500 shares worth $1.17M. The stake represents 2.34% of the portfolio and ranks #14 among its holdings.

1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Glaxis Capital Management held 5,500 shares of Quest Diagnostics worth $1.17M as of Q2 2026.
Quest Diagnostics was a new Glaxis Capital Management position in Q2 2026.
Quest Diagnostics made up 2.34% of Glaxis Capital Management's portfolio in Q2 2026, its #14 holding.
1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Glaxis Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.